VRT 106
Alternative Names: M1 c6v1; Recombinant oncolytic virus M1 - Guangzhou Virotech Pharmaceutical; VRT-106Latest Information Update: 05 Aug 2025
At a glance
- Originator Guangzhou Virotech Pharmaceutical
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glioblastoma; Pancreatic cancer
- Phase I Solid tumours
Most Recent Events
- 16 Jul 2025 Phase-I/II clinical trials in Glioblastoma (Recurrent) in China (IV) (NCT07093814)
- 19 Mar 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT06826313)
- 12 Mar 2025 Xiangya Hospital of Central South University plans a phase I/II trial for Pancreatic Cancer (Late stage disease, Metastatic disease, First line therapy, Combination therapy, Unresectable/Inoperable) in China (IV) in March 2025 (NCT06866977)